Oculis Holding AG OCS 深 沪
已收盘 08-07 16:00:00 美东时间
12.68
+0.300
+2.42%
华盛通- 最 高13.28
- 今 开12.95
- 成交量 37.09万股
- 最 低 12.41
- 昨 收 12.38
- 总市值 7.66亿
- 52周最高 34.475
- 市盈率 静 --
- 换手率 0.61%
- 52周最低 10.52
- 委 比 40.00%
- 总股本 6038.81万
- 历史最高 34.475
- 量 比 1.12
- 振 幅 7.03%
- 历史最低 6.26
- 每 手 1
- 风险率 5.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.48) by 58.33 percent. This is a 64.91 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $392.150 thousan...
08-07 15:54
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis Holding AG announced positive FDA pre-IND feedback for Privosegtor in acute multiple sclerosis (MS) relapses. The FDA supports the regulatory pathway and confirms existing data can be used for an IND submission in the fourth quarter of 2026. Privosegtor, a neuroprotective candidate, has shown promise in optic neuritis and aims to address unmet needs in MS relapse treatment. Oculis plans to host an R&D Day later this year to provide further...
08-03 08:00
Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 2% on Friday. Shares of Intuitive Surgical Inc (NASDAQ:ISRG) fell sharply in pre-market trading after the company reported second-quarter financial results. Intuitive Surgical reported quarterly earnings of $2.80 ...
07-17 20:02
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Oculis Holding AG announced its participation in the Piper Sandler Virtual Ophthalmology Conference, where management will discuss its late-stage pipeline. Key highlights include Privosegtor, a neuroprotective candidate with FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis, targeting a $7B+ market, and Licaminlimab, a topical anti-TNFα for dry eye disease. The Company is well-positioned to achieve value-driving milestones, f...
07-02 08:00
Oculis Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab For Dry Eye Disease
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial targets the specific TNFR1
06-09 16:16
Oculis三期临床试验失败致股价暴跌，多家律所启动证券欺诈调查
生物制药公司Oculis Holding AG（纳斯达克代码：OCS）正面临多家股东权益律师事务所的证券欺诈调查。继2026年5月29日披露其核心候选药物...
06-09 03:47
Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky
Oculis Holding AG shares collapsed approximately 23% after Phase 3 DIAMOND trials for lead product OCS-01 failed to meet the primary endpoint in diabetic macular edema. NEW YORK, June 8, 202...
06-08 21:00
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Oculis Holding AG announced its participation in the 47th Annual Goldman Sachs Global Healthcare Conference, where its management will discuss its innovative pipeline. Key highlights include Privosegtor, a neuroprotective candidate with Breakthrough Therapy and PRIME designations for optic neuritis, targeting a $7B+ market in the U.S., and Licaminlimab, a topical anti-TNFα for dry eye disease as the first genotype-based precision medicine. With a...
06-08 18:45
股价暴跌！糖尿病黄斑水肿DME 3期失败，不计划NDA
药融圈数据监测显示：近期2026 年 5 月 29 日，总部位于瑞士楚格的全球生物制药公司 Oculis Holding AG（NASDAQ:OCS）公布其核心...
06-08 13:52
